A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
Headquartered in Building Two, Galway Fiscal year ends April NYSE: MDT medtronic.com
Medtronic plc is a global healthcare technology company that develops and manufactures medical devices and therapies across cardiovascular, neuroscience, medical surgical, and diabetes care. The company's portfolio spans cardiac devices (including pacemakers, defibrillators, cardiac ablation systems, and structural heart solutions), cranial and spinal surgical technologies, surgical robotics, neuromodulation therapies, patient monitoring systems, insulin pumps, and continuous glucose monitors. Medtronic serves healthcare systems in more than 150 countries with approximately 95,000 employees. The company is in the process of separating its Diabetes business through potential capital markets transactions, which may include a spin-off, split-off, or offering. In fiscal 2027, the Cardiovascular Portfolio was reorganized into Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health divisions. The company trades on the NYSE under the ticker MDT. Updated
A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
Medtronic just set a fresh 52-week high at $105.02, 2.97% above its prior peak from November 2025. The medtech giant has erased a spring slide that took it under $74.
A 4.57% climb to $104.81 adds roughly $6 billion to a $134.1 billion medical-device giant, and megacaps this size rarely move that far in a single session. Keep an eye on whether it holds above the $100.23 open.
The call is that falling long rates are repricing everything outside tech right now rather than earnings, and Cramer says growth stocks away from semis are the clean way to play it. He is warning Apple holders that guidance will disappoint even after a record quarter, and he is openly annoyed at Oracle for raising capital immediately after promising restraint.
Medtronic's CEO just took $4.75 million off the table, trimming 18% of his personal stake right after the company raised fiscal 2027 guidance. No 10b5-1 plan was disclosed on the filing, which makes it a discretionary sale.
Cramer's point for anyone holding bank stocks: solid results are no longer being rewarded, and the charts have turned ugly regardless. The bigger swing factor is oil. If the war ends, he expects crude to be cut in half, which would reset inflation and the Fed debate overnight.
Cramer wants to add software as the bounce-back trade and the beaten-down industrial names tied to data center power. He also warns that rising rates are the real threat heading into earnings season in a couple of weeks.
Healthcare demand holds up when the economy slows, which makes the sector a natural place for retirees to look for income heading into the new year. The quality of that income varies…
When Washington stalls, most investors worry about their portfolios. Income seekers have a different play: four payers from four sectors that need no new law to keep raising dividends, including one with…
A heart device maker, a bomber builder, and a garbage hauler all raised their payouts in 2020, when the economy stalled. Their yields look small, but the cash behind them tells a…
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows,…
Retirees who want income that keeps coming through recessions, rate swings and market scares often start with health care. People need heart devices, diagnostic tests and cancer drugs in every economy, and…
Democrats won control of both the House and the Senate, while Republicans still control the White House. The result is divided government, which usually brings legislative gridlock. Gridlock tends to reward income…
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could…
Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster. Whether explosive growth in cardiac ablation can close…
A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it. These five blue chips clear that bar, and…
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics. Three healthcare stocks prove that the most reliable paycheck…
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than…
A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising…
One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind…
Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why…
Medtronic plc is a global healthcare technology company that develops and manufactures medical devices and therapies across cardiovascular, neuroscience, medical surgical, and diabetes care.
24/7 Wall St.'s 12-month price target for MDT is $120.38, rated Buy. The Wall Street consensus target is $105.00. MDT price prediction →